1. Home
  2. BAK vs WVE Comparison

BAK vs WVE Comparison

Compare BAK & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Braskem SA ADR

BAK

Braskem SA ADR

HOLD

Current Price

$2.84

Market Cap

1.2B

Sector

Industrials

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$7.43

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAK
WVE
Founded
1972
2012
Country
Brazil
Singapore
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
BAK
WVE
Price
$2.84
$7.43
Analyst Decision
Hold
Strong Buy
Analyst Count
2
12
Target Price
$4.40
$19.08
AVG Volume (30 Days)
1.2M
2.4M
Earning Date
11-11-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,841,708,237.00
$109,230,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$8.62
$6.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
103.75
52 Week Low
$2.32
$5.28
52 Week High
$5.26
$16.38

Technical Indicators

Market Signals
Indicator
BAK
WVE
Relative Strength Index (RSI) 51.63 48.99
Support Level $2.89 $6.60
Resistance Level $3.05 $7.78
Average True Range (ATR) 0.18 0.43
MACD -0.01 0.06
Stochastic Oscillator 24.30 68.24

Price Performance

Historical Comparison
BAK
WVE

About BAK Braskem SA ADR

Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: